Eli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlist
Eli Lilly dips: Shares...obesity drug demonstrated promise in a Phase 1 study. It's not a surprise to see Lilly's stock down on the threat of another new potential entrant ...
CNBC
5 小時前